High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
- 11 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (5), 693-698
- https://doi.org/10.1038/s41591-020-0860-1
Abstract
Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade1, this has not been comprehensively evaluated in large randomized studies. Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral blood mononuclear cells and tumors of patients treated with atezolizumab (anti-PD-L1 monoclonal antibody) from multiple randomized trials representing 1,445 patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma. High levels of IL-8 in plasma, peripheral blood mononuclear cells and tumors were associated with decreased efficacy of atezolizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classically CD8+ T cell inflamed. Low baseline pIL-8 in patients with mUC was associated with increased response to atezolizumab and chemotherapy. Patients with mUC who experienced on-treatment decreases in pIL-8 exhibited improved overall survival when treated with atezolizumab but not with chemotherapy. Single-cell RNA sequencing of the immune compartment showed that IL8 is primarily expressed in circulating and intratumoral myeloid cells and that high IL8 expression is associated with downregulation of the antigen-presentation machinery. Therapies that can reverse the impacts of IL-8-mediated myeloid inflammation will be essential for improving outcomes of patients treated with immune checkpoint inhibitors.Keywords
Funding Information
- Genentech, Inc
- Roche/Genentech, Inc
- Roche
- Dana-Farber/Harvard Cancer Center (5P50CA101942)
This publication has 35 references indexed in Scilit:
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue OriginsClinical Cancer Research, 2014
- Software for Computing and Annotating Genomic RangesPLoS Computational Biology, 2013
- Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growthNature Medicine, 2012
- Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasisBritish Journal of Cancer, 2012
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Differential macrophage programming in the tumor microenvironmentTrends in Immunology, 2012
- IL-8 Signaling Plays a Critical Role in the Epithelial–Mesenchymal Transition of Human Carcinoma CellsCancer Research, 2011
- Fast and SNP-tolerant detection of complex variants and splicing in short readsBioinformatics, 2010
- The chemokine system in diverse forms of macrophage activation and polarizationTrends in Immunology, 2004
- Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.JCI Insight, 1989